Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2005 June; 6(2): E245–E252.
Published online 2005 October 6. doi:  10.1208/pt060235
PMCID: PMC2750538

Quantifying crystal form content in physical mixtures of (±)-tartaric acid and (+)-tartaric acid using near infrared reflectance spectroscopy


The objective of this study was to use diffuse reflectance near infrared spectroscopy (NIRS) to determine racemic compound content in physical mixtures composed primarily of the enantiomorph and to assess the error, instrument reproducibility and limits of detection (LOD) and quantification (LOQ) of the method. Physical mixtures ranging from 0 to 25% (±)-tartaric acid in (+)-tartaric acid were prepared and spectra of the powder samples contained in glass vials were obtained using a Foss NIRSystems Model 5000 monochrometer equipped with a Rapid Content Analyzer scanning from 1100 to 2500 nm. A calibration curve was constructed by plotting (±)-tartaric acid weight percent against the 2nd derivative values of log (1/R) vs λ at a single wavelength, normalized with a denominator wavelength (1480 nm/1280 nm). Excellent linearity was observed (R2=0.9999). The standard error of calibration (SEC) was 0.07 and the standard error of prediction (SEP) for the validation set was 0.11. Instrument and method errors for samples in the 2% composition range ((±)-tartaric acid in (+)-tartaric acid) were less than 1% RSD and 3% RSD, respectively. The practical LOD and LOQ were 0.1% and 0.5%, respectively, and comparable to the calculated LOD and LOQ. These studies show that NIRS can be used as a rapid and sensitive quantitative method for determining racemate content in the presence of the enatiomerically pure crystal in the solid-state.

Keywords: Tartaric Acid, near-infrared spectroscopy, crystal form, quantification, enantiomers, racemate

Full Text

The Full Text of this article is available as a PDF (364K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Millership JS, Fitzpatrick A. Commonly used chiral drugs: a survey. Chirality. 1993;5:573–576. doi: 10.1002/chir.530050802. [PubMed] [Cross Ref]
2. Drayer DE. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: overview. Clin Pharmacol Ther. 1986;40:125–133. doi: 10.1038/clpt.1986.150. [PubMed] [Cross Ref]
3. Jacques J, Collet A, Wilen SH. Enantiomers, Racemates and Resolutions. New York, NY: John Wiley & Sons; 1981.
4. Duddu SP, Grant DJ. Effects of configuration around the chiral carbon atoms on the crystal properties of ephedrinium and pseudoephedrinium salicylates. Pharm Res. 1994;11:1549–1556. doi: 10.1023/A:1018945401484. [PubMed] [Cross Ref]
5. Piyarom S, Yonemochi E, Oguchi T, Yamamoto K. Effects of grinding and humidification on the transformation of conglomerate to racemic compound in optically active drugs. J Pharm Pharmacol. 1997;49:384–389. [PubMed]
6. Calatozzolo M, Celentano G, Clerici F, Giammarusti G, Stradi R. FT-IR spectroscopy for the evaluation of the enantiomeric purity of levodropropizine: comparison with HPLC analysis. Boll Chim Pharm. 1993;132:467–471.
7. Phadnis NV, Suryanarayanan R. Simultaneous quantification of an enantiomer and the racemic compound of ibuprofen by X-ray powder diffractometry. Pharm Res. 1997;14:1176–1180. doi: 10.1023/A:1012198605891. [PubMed] [Cross Ref]
8. Stahly GP, McKenzie AT, Andres MC, Russell CA, Johnson P. Determination of the optical purity of ibuprofen using X-ray powder diffraction. J Pharm Sci. 1997;86:970–971. doi: 10.1021/js9700715. [PubMed] [Cross Ref]
9. Jaroszewski JW, Olsson A. Determination of enantiomeric purity of nicotine in pharmaceutical preparations by13C-NMR in the presence of chiral lanthanide shift reagent. J Pharm Biomed Anal. 1994;12:295–299. doi: 10.1016/0731-7085(94)90002-7. [PubMed] [Cross Ref]
10. Hanna GM. Determination of enantiomeric composition of ibuprofen in bulk drug by proton nuclear magnetic resonance spectroscopy with a chiral lanthanide chelate. J Pharm Biomed Anal. 1997;15:1805–1811. doi: 10.1016/S0731-7085(96)02042-0. [PubMed] [Cross Ref]
11. Hill HDW, Zens AP, Jacobus J. Solid-state NMR spectroscopy, distinction of diastereomers and determination of optical purity. J Am Chem Soc. 1979;101:7090–7091. doi: 10.1021/ja00517a063. [Cross Ref]
12. Elsabee M, Prankerd RJ. Solid-state properties of drugs. Part 3. Differential scanning calorimetry of chiral drug mixtures existing as racemic solid solutions, racemic mixtures or racemic compounds. Int J Pharm. 1992;86:221–230. doi: 10.1016/0378-5173(92)90200-L. [Cross Ref]
13. Buchanan BR, Ciurczak EW, Grunke AQ, Honigs DE. Determination of enantiomeric purity of valine via Near-infrared reflectance spectroscopy. Spectroscopy. 1988;3:54–56.
14. Luner PE, Majuru S, Seyer JJ, Kemper MS. Quantifying crystalline form composition in binary powder mixtures using near-infrared reflectance spectroscopy. Pharm Dev Technol. 2000;5:231–246. doi: 10.1081/PDT-100100538. [PubMed] [Cross Ref]
15. Seyer JJ, Luner PE, Kemper MS. Application of diffuse reflectance near-infrared spectroscopy for determination of crystallinity. J Pharm Sci. 2000;89:1305–1316. doi: 10.1002/1520-6017(200010)89:10<1305::AID-JPS8>3.0.CO;2-Q. [PubMed] [Cross Ref]
16. The United States Pharmacopeia . USP24. Rockville, MD: US Pharmacopeial Convention; 2000. pp. 2149–2152.
17. Powder Diffraction File. Swarthmore, PA: International Center for Diffraction Data, 1989.
18. Kirsch JD, Drennen JK. Near-infrared spectroscopy: applications in the analysis of tablets and solid pharmaceutical dosage forms. Appl Spectrosc Rev. 1995;30:139–174. doi: 10.1080/05704929508000906. [Cross Ref]
19. Workman JJ. Interpretive Spectroscopy for Near Infrared. Appl Spectrosc Rev. 1996;31:251–320. doi: 10.1080/05704929608000571. [Cross Ref]
20. Luner PE, Patel AD, Swenson DC. (+/-)-tartaric acid. Acta Crystallogr C. 2002;58:O333–O335. doi: 10.1107/S0108270102006650. [PubMed] [Cross Ref]
21. Patel AD, Swenson DC, Luner PE. Solid-state characterization and crystal structure of dl-tartaric acid. PharmSci. 2000;2:3587–3587.
22. Patel AD. Solid-state characterization and quantitative analysis of crystal forms using near infrared reflectance spectroscopy. Iowa City, Iowa: University of Iowa, College of Pharmacy; 2000.
23. Honigs DE. Near infrared analysis. Anal Instrum. 1985;14:1–62. doi: 10.1080/10739148508543566. [Cross Ref]
24. Workman JJ. NIR Calibration. In: Burns DA, Ciurczak E, editors. Practical Spectroscopy Series: Handbook of Near-Infrared Analysis. 1st ed. New York: Marcel Dekker Inc; 1992. pp. 274–275.
25. Borer MW, Zhou X, Hays DM, Hofer JD, White KC. Evaluation of key sources of variability in the measurement of pharmaceutical drug products by near infrared reflectance spectroscopy. J Pharm Biomed Anal. 1998;17:641–650. doi: 10.1016/S0731-7085(97)00229-X. [PubMed] [Cross Ref]
26. Yoon WL, Jee RD, Moffat AC. Optimisation of sample presentation for the near-infrared spectra of pharmaceutical excipients. Analyst. 1998;123:1029–1034. doi: 10.1039/a800358k. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists